Iovance Biotherapeutics, Inc. (IOVA)
8.07
-0.22
(-2.65%)
USD |
NASDAQ |
Aug 24, 16:00
8.05
-0.02
(-0.25%)
After-Hours: 20:00
Iovance Biotherapeutics Debt to Equity Ratio : 0.0625 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0625 |
| March 31, 2026 | 0.0662 |
| December 31, 2025 | 0.0708 |
| September 30, 2025 | 0.0747 |
| June 30, 2025 | 0.0761 |
| March 31, 2025 | 0.07 |
| December 31, 2024 | 0.082 |
| September 30, 2024 | 0.1021 |
| June 30, 2024 | 0.1063 |
| March 31, 2024 | 0.1241 |
| December 31, 2023 | 0.1298 |
| September 30, 2023 | 0.1179 |
| June 30, 2023 | 0.1395 |
| March 31, 2023 | 0.1248 |
| December 31, 2022 | 0.171 |
| September 30, 2022 | 0.2035 |
| June 30, 2022 | 0.1703 |
| March 31, 2022 | 0.1447 |
| December 31, 2021 | 0.1151 |
| September 30, 2021 | 0.1036 |
| June 30, 2021 | 0.0702 |
| March 31, 2021 | 0.0834 |
| December 31, 2020 | 0.0787 |
| September 30, 2020 | 0.0153 |
| June 30, 2020 | 0.0104 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0391 |
| December 31, 2019 | 0.0385 |
| September 30, 2019 | 0.0405 |
| June 30, 2019 | 0.0304 |
| March 31, 2019 | 0.024 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Neurocrine Biosciences, Inc. | 0.1088 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 915.53M |
| Total Liabilities (Quarterly) | 179.49M |
| Shareholders Equity (Quarterly) | 736.04M |
| Current Ratio | 4.345 |
| Net Debt Paydown Yield | 0.08% |